The Black Box Warning for Topical Calcineurin Inhibitors: Looking Outside the Box
Overview
Pulmonary Medicine
Affiliations
Kim M, Kong D, Kim N, Kim M, Kim H, Choi J BMC Vet Res. 2025; 21(1):115.
PMID: 40011929 PMC: 11866708. DOI: 10.1186/s12917-025-04554-w.
Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis.
Moreno A, Renert-Yuval Y, Guttman-Yassky E Expert Rev Clin Pharmacol. 2023; 16(2):119-131.
PMID: 36705936 PMC: 9947941. DOI: 10.1080/17512433.2023.2173172.
Okada K, Asakura S, Yano T, Kishimoto T Int J Hematol. 2018; 108(3):329-334.
PMID: 29516290 DOI: 10.1007/s12185-018-2426-2.
Atopic dermatitis and the atopic march: what is new?.
Patrizi A, Pileri A, Bellini F, Raone B, Neri I, Ricci G J Allergy (Cairo). 2011; 2011:279425.
PMID: 21941575 PMC: 3173727. DOI: 10.1155/2011/279425.
The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.
Ring J, Mohrenschlager M, Henkel V Drug Saf. 2008; 31(3):185-98.
PMID: 18302444 DOI: 10.2165/00002018-200831030-00001.